Celino Co., Ltd. signed a contract to acquire CM business division of MEDIPOST Co., Ltd. for approximately KRW 940 million.
February 31, 2019
Share
Celino Co., Ltd. signed a contract to acquire CM business division of MEDIPOST Co., Ltd. for approximately KRW 940 million on February 1, 2019. Consideration will be received in cash on February 1, 2019. The transfer price will be adjusted to reflect the increase or decrease in the amount of the sales due to changes in the financial condition between December 31, 2018 and the contract date. The transaction is expected to be completed on February 1, 2019. Charm Accounting Corporation acted as external rating institute under the transaction.
MEDIPOST Co., Ltd. is a Korea-based company engaged in the biotechnology business. The Company mainly operates cord blood banks. Its cord blood banks consist of public cord blood bank, which provides resource to anyone who may need to undergo hematopoietic stem cell transplantation (HSCT) as a result of blood-related diseases, such as leukemia or aplastic anemia, as well as family cord blood bank, which provides services for storing newbornâs cord blood exclusively for familyâs use. It also involves in the provision of stem cell drugs, which are used for recovery of knee articular cartilage and others, distribution of healthcare food and natural cosmetics, as well as provision of healthcare services.
MEDIPOST CO., LTD. 
